32 algorithm-development-"Multiple"-"Simons-Foundation"-"Prof"-"UNIS" positions in Switzerland
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
from this research inform the development of new diagnostics, treatments, and vaccines against malaria, tuberculosis, schistosomiasis, Chagas and other neglected tropical diseases. For the Epidemiology
-
. Empa is a research institution of the ETH Domain. The Coating Technologies Group in Empa's Laboratory for Surface Science & Coating Technologies develops next-generation functional thin-films through
-
the Laboratory of Nano Particles at Empa and also matriculate in ETH Zürich. The research focuses on developing innovative plasmonic materials. Surface plasmon resonance (SPR) and localized surface
-
to muon g-2 from lattice Quantum Chromodynamics and algorithmic developments for multi-level and RG-improved simulations (research group of Urs Wenger) C.) Study of multi-hadron systems, with a focus on
-
learning with the physics of laser–matter interaction. Your developments will be directly validated through multiple experimental runs on state-of-the-art laser processing equipment. You will work closely
-
from this research inform the development of new diagnostics, treatments, and vaccines against malaria, tuberculosis, schistosomiasis, Chagas and other neglected tropical diseases. Are you excited by
-
trapping and analysis using state-of-the-art nanopore experiments. About the Project Our group has pioneered the development of the Nanopore Electro-Osmotic Trap (NEOtrap), a groundbreaking technique that
-
of nanoparticles for healthcare and industrial applications. As a PhD candidate, you will: Develop and refine SAXS and FCCS methods to quantify size, concentration, density and internal structure of diverse
-
-bleaching of the fluorescent dyes involved, which ends the experiment prematurely, rendering many biological questions inaccessible. To bypass this limitation, our group has developed DyeCycling/FRET, where
-
clinical scientists to advance our understanding of health and disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800